Condition: Asthma
Interventions: Drug: QAV680; Drug: QAV680 Placebo
Sponsor: Novartis Pharmaceuticals
Terminated – verified September 2010
View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days
Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma
Condition: Asthma
Interventions: Drug: Tiotropium bromide; Drug: tiotropium bromide; Drug: tiotropium bromide; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting – verified September 2010
View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days
A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma
Condition: Asthma
Interventions: Drug: Placebo; Drug: Tiotropium 5 µg q.d.; Drug: Tiotropium 2.5 µg b.i.d.
Sponsors: Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting – verified September 2010
View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days
Evaluation of Tiotropium 2.5 and 5 Mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 Mcg Twice Daily) in Patient With Moderate Persistent Asthma II
Condition: Asthma
Interventions: Drug: 50 mcg salmeterol HFA MDI; Drug: placebo; Drug: 5 mcg tiotropium Respimat®; Drug: 2.5 mcg tiotropium Respimat®
Sponsors: Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting – verified September 2010
View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days